| CTRI Number |
CTRI/2026/01/101806 [Registered on: 22/01/2026] Trial Registered Prospectively |
| Last Modified On: |
21/01/2026 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Homeopathy |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
A Clinical Study To Evaluate The Effect Of The Homoeopathic Medicine Tellurium Metallicum In LM Potency (Fifty Millesimal/ Fifty-Thousand Dilution Potency/ High Dilution Potency) For Treatment Of Ringworm (Tinea Corporis) In Patients Aged 20 To 50 Years |
|
Scientific Title of Study
|
Effectiveness Of Tellurium Metallicum In LM Potencies For Management Of Tinea Corporis Among Patients Aged 20 To 50 Years By Using TCS: A Prospective Single Arm Study |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
ClinicalTrials.gov |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Ishita Jignesh Khant |
| Designation |
PG Scholar |
| Affiliation |
Parul Institute of Homoeopathy and Research Hospital |
| Address |
Parul Institute of Homoeopathy and Research Hospital, 3rd Floor, Room No. 401, Department of Homoeopathic Pharmacy, At. Ishwarpura, Po. Limda, Ta. Waghodia, Di. Vadodara
Vadodara
GUJARAT
391760
India |
| Phone |
9016362020 |
| Fax |
|
| Email |
2404402100002@paruluniversity.ac.in |
|
Details of Contact Person
Scientific Query
|
| Name |
Santosh Reddy |
| Designation |
HOD & Professor of Department of Homoeopathic Pharmacy |
| Affiliation |
Parul Institute of Homoeopathy and Research Hospital |
| Address |
Parul Institute of Homoeopathy and Research Hospital, 3rd Floor, Room No. 401, Department of Homoeopathic Pharmacy, At. Ishwarpura, Po. Limda, Ta. Waghodia, Di. Vadodara
Vadodara
GUJARAT
391760
India |
| Phone |
9663875835 |
| Fax |
|
| Email |
santosh.hudgikar28869@paruluniversity.ac.in |
|
Details of Contact Person
Public Query
|
| Name |
Ishita Jignesh Khant |
| Designation |
PG Scholar |
| Affiliation |
Parul Institute of Homoeopathy and Research Hospital |
| Address |
Parul Institute of Homoeopathy and Research Hospital, 3rd Floor, Room No. 401, Department of Homoeopathic Pharmacy, At. Ishwarpura, Po. Limda, Ta. Waghodia, Di. Vadodara
Vadodara
GUJARAT
391760
India |
| Phone |
9016362020 |
| Fax |
|
| Email |
2404402100002@paruluniversity.ac.in |
|
|
Source of Monetary or Material Support
|
| Parul Institute of Homoeopathy and Research Hospital, 3rd Floor, Room No. 401, Department of Homoeopathic Pharmacy, At. Ishwarpura, Po. Limda, Ta. Waghodia, Di. Vadodara- 391760 |
|
|
Primary Sponsor
|
| Name |
Parul Institute of Homoeopathy and Research |
| Address |
Parul Institute of Homoeopathy and Research, At. Ishwarpura, Po. Limda, Ta. Waghodia, Di. Vadodara - 391760 |
| Type of Sponsor |
Research institution and hospital |
|
|
Details of Secondary Sponsor
|
| Name |
Address |
| Ishita Jignesh Khant |
Parul Institute of Homoeopathy and Research, At. Ishwarpura, Po. Limda, Ta. Waghodia, Di. Vadodara - 391760 |
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Ishita Jignesh Khant |
Parul Institute of Homoeopathy and Research Hospital |
Parul Institute of Homoeopathy and Research Hospital, 3rd Floor, Room No. 401, Department of Homoeopathic Pharmacy, At. Ishwarpura, Po. Limda, Ta. Waghodia, Di. Vadodara - 391760
Vadodara
GUJARAT |
9016362020
2404402100002@paruluniversity.ac.in |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethical Committee for Human Research |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: B354||Tinea corporis, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
Not Applicable |
Not Applicable |
| Intervention |
Tellurium metallicum |
In this intervention, tellurium metallicum in LM (50 millesimal) potencies will be used as the only homeopathic medicine to treat patients suffering from tinea corporis (ringworm of the body). The medicine will be given in liquid form. It will be prepared by dissolving one medicated pill of tellurium metallicum LM potency in a bottle that is filled three-fourths with distilled water and preserved with 15–20 drops of alcohol. Before every dose, the bottle will be shaken ten times downward. Treatment for every patient will start with LM 0/1 potency, and higher potencies such as LM 0/2, LM 0/3, LM 0/4 and so on will be given later depending on how well the patient improves. Improvement will be judged based on reduction in size of the lesions, redness, scaling, itching and border visibility. One teaspoon of the medicine will be taken by mouth once daily or as required. Each patient will be treated for up to six weeks. During the study period, patients will not be allowed to use any other allopathic, homeopathic, ayurvedic or antifungal medicines. Patients will be examined every week, and their improvement will be assessed. |
|
|
Inclusion Criteria
|
| Age From |
20.00 Year(s) |
| Age To |
50.00 Year(s) |
| Gender |
Both |
| Details |
Cases which are clinically diagnosed according to ICD-10 CM, B35.4 criteria.
All socio-economic status.
Patient who will provide informed consent. |
|
| ExclusionCriteria |
| Details |
Patient who are taking simultaneously any other treatment for the tinea corporis.
Patients with any type of severe systemic illnesses.
Pregnant and lactating women. |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To assess the effectiveness of tellurium metallicum in LM potencies for management of tinea corporis among patients aged 20 to 50 years. |
2 Months |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To assess clinical improvement in patients of tinea corporis using the tinea corporis score (TCS) during the course of treatment. |
2 Months |
|
|
Target Sample Size
|
Total Sample Size="32"
Sample Size from India="32"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 1 |
|
Date of First Enrollment (India)
|
02/03/2026 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1"
Months="0"
Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Tinea corporis is a common and recurrent superficial fungal infection in India, particularly affecting individuals aged 20–50 years, with growing resistance and adverse effects associated with conventional antifungal therapies. Tellurium metallicum, a well-indicated homoeopathic remedy for ring-shaped, pruritic, and offensive skin lesions, closely corresponds to the clinical presentation of tinea corporis; however, clinical evidence for its effectiveness in LM potencies remains limited. This prospective single-arm study aims to evaluate the effectiveness of Tellurium metallicum in LM potencies for the management of tinea corporis using the Tinea Corporis Score (TCS). A total of 32 clinically diagnosed patients (ICD-10 CM B35.4), aged 20–50 years, will be enrolled through purposive sampling from the OPD and IPD of Parul Institute of Homoeopathy and Research Hospital, Vadodara. Tellurium metallicum will be administered orally in liquid form, starting from LM 0/1 and adjusted according to clinical response, with weekly follow-up for up to 6 weeks. Treatment outcomes will be assessed using TCS, and the collected data will be statistically analyzed to determine the clinical effectiveness of the intervention.
|